Danaher Acquires Masimo, Anticipates Future Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy DHR?
Source: Fool
- Historical Performance Review: Since its founding in 1969, Danaher has achieved over 52,700% stock returns; however, following the COVID-19 pandemic, shares have dropped 36%, leading investors to question its future performance.
- Strategic Significance of Masimo Acquisition: Danaher is acquiring pulse oximetry leader Masimo for $9.9 billion, expected to add $530 million in EBITDA by 2027, thereby enhancing its competitive edge in the diagnostics sector.
- Financial Recovery Signs: Revenue began to rebound in mid-2024, with first-quarter non-GAAP earnings growing 9.5% year-over-year, surpassing Wall Street expectations, indicating the company's potential for market recovery.
- Future Growth Expectations: Analysts project Danaher to grow earnings by 8% to 9% annually over the next three to five years, and with a current P/E ratio of 22, the stock appears attractive for long-term investment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 166.520
Low
240.00
Averages
266.18
High
310.00
Current: 166.520
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Danaher CEO to Present at Healthcare Conference
- Conference Details: Danaher Corporation's CEO Rainer M. Blair will present at the Bank of America Securities Healthcare Conference on May 13, 2026, at 11:20 AM PT in Las Vegas, showcasing the company's innovations in life sciences and diagnostics.
- Live Webcast: The event will be simultaneously webcast on Danaher's website, allowing global investors and stakeholders to gain real-time insights into the company's latest developments and strategic direction, thereby enhancing transparency and investor confidence.
- Company Vision: Danaher is committed to improving human health through the power of science and technology, leveraging its industry-leading business ecosystem to help customers tackle complex scientific and clinical challenges, accelerating the discovery and delivery of innovations.
- Global Impact: With approximately 60,000 associates worldwide, the company focuses on driving improvements in global health quality through continuous improvement and operational excellence, demonstrating its leadership and social responsibility in the global life sciences sector.
See More
OEF Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: OEF's 52-week low is $269.21 and high is $362.45, with the latest trade at $362.44, indicating the stock is near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing for flexibility in response to market demand, as these units can be created or destroyed.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Danaher Announces Quarterly Cash Dividend
- Quarterly Cash Dividend: Danaher Corporation's Board of Directors has approved a regular cash dividend of $0.40 per share, payable on July 31, 2026, reflecting the company's stable financial position and commitment to shareholders.
- Record Date for Shareholders: The record date for this dividend is June 26, 2026, ensuring that eligible shareholders receive their dividends promptly, which further enhances investor confidence.
- Company Background: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through the power of science and technology, showcasing its leadership in the industry.
- Innovation-Driven: The company aims to accelerate the discovery and delivery of innovations through its advanced science and technology and continuous operational excellence, reflecting its commitment to enhancing global quality of life and sustainable development.
See More
Analysis of Investment Opportunities in Dividend Stocks
- Dividend Growth Potential: Trivariate Research highlights that the median dividend growth rate among 479 large-cap stocks is 5% annually, with these stocks outperforming the top 700 equities over both 25-year and 5-year periods, underscoring the significance of dividends as a durable return factor.
- Low Payout Ratio Advantage: The study found that stocks in the lowest payout ratio quintiles performed best over the past five years, particularly those with cash to market cap above 25%, as they significantly outperform others when increasing dividends, reflecting strong financial health.
- Synchrony Financial's Dividend Increase: Synchrony Financial announced a 13% dividend increase to $0.34 per share and a share repurchase program of up to $6.5 billion, demonstrating confidence in long-term shareholder value, despite its stock being down nearly 11% year to date.
- Travelers Insurance's Sustained Growth: Travelers Insurance declared a 14% increase in its quarterly dividend to $1.25 per share, marking its 22nd consecutive year of increases with an 8% compound annual growth rate, showcasing its ability to deliver industry-leading returns with low volatility.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Danaher CEO to Present at Healthcare Conference
- Conference Details: Danaher Corporation's CEO Rainer M. Blair will present at the Bank of America Securities Healthcare Conference on May 13, 2026, at 11:20 AM PT in Las Vegas, showcasing the company's innovations in life sciences and diagnostics.
- Live Webcast: The event will be simultaneously webcast on Danaher's website, allowing global investors and stakeholders to gain real-time insights into the company's latest developments and strategic direction, thereby enhancing transparency and investor confidence.
- Company Vision: Danaher is committed to improving human health through the power of science and technology, leveraging its industry-leading business ecosystem to help customers tackle complex scientific and clinical challenges, accelerating the discovery and delivery of innovations.
- Global Impact: With approximately 60,000 associates worldwide, the company focuses on driving improvements in global health quality through continuous improvement and operational excellence, demonstrating its leadership and social responsibility in the global life sciences sector.
See More
OEF Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: OEF's 52-week low is $269.21 and high is $362.45, with the latest trade at $362.44, indicating the stock is near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessments.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing for flexibility in response to market demand, as these units can be created or destroyed.
- Liquidity Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows or outflows, where inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Danaher Announces Quarterly Cash Dividend
- Quarterly Cash Dividend: Danaher Corporation's Board of Directors has approved a regular cash dividend of $0.40 per share, payable on July 31, 2026, reflecting the company's stable financial position and commitment to shareholders.
- Record Date for Shareholders: The record date for this dividend is June 26, 2026, ensuring that eligible shareholders receive their dividends promptly, which further enhances investor confidence.
- Company Background: Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through the power of science and technology, showcasing its leadership in the industry.
- Innovation-Driven: The company aims to accelerate the discovery and delivery of innovations through its advanced science and technology and continuous operational excellence, reflecting its commitment to enhancing global quality of life and sustainable development.
See More
Analysis of Investment Opportunities in Dividend Stocks
- Dividend Growth Potential: Trivariate Research highlights that the median dividend growth rate among 479 large-cap stocks is 5% annually, with these stocks outperforming the top 700 equities over both 25-year and 5-year periods, underscoring the significance of dividends as a durable return factor.
- Low Payout Ratio Advantage: The study found that stocks in the lowest payout ratio quintiles performed best over the past five years, particularly those with cash to market cap above 25%, as they significantly outperform others when increasing dividends, reflecting strong financial health.
- Synchrony Financial's Dividend Increase: Synchrony Financial announced a 13% dividend increase to $0.34 per share and a share repurchase program of up to $6.5 billion, demonstrating confidence in long-term shareholder value, despite its stock being down nearly 11% year to date.
- Travelers Insurance's Sustained Growth: Travelers Insurance declared a 14% increase in its quarterly dividend to $1.25 per share, marking its 22nd consecutive year of increases with an 8% compound annual growth rate, showcasing its ability to deliver industry-leading returns with low volatility.
See More
